IL149890A0 - Tnt-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated - Google Patents
Tnt-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediatedInfo
- Publication number
- IL149890A0 IL149890A0 IL14989000A IL14989000A IL149890A0 IL 149890 A0 IL149890 A0 IL 149890A0 IL 14989000 A IL14989000 A IL 14989000A IL 14989000 A IL14989000 A IL 14989000A IL 149890 A0 IL149890 A0 IL 149890A0
- Authority
- IL
- Israel
- Prior art keywords
- antagonist
- lfa
- alpha
- tnf
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17069699P | 1999-12-14 | 1999-12-14 | |
| PCT/US2000/033875 WO2001043773A1 (en) | 1999-12-14 | 2000-12-14 | Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL149890A0 true IL149890A0 (en) | 2002-11-10 |
Family
ID=22620900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14989000A IL149890A0 (en) | 1999-12-14 | 2000-12-14 | Tnt-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20010031260A1 (pt) |
| EP (1) | EP1237575B1 (pt) |
| JP (1) | JP2003517022A (pt) |
| KR (1) | KR100567292B1 (pt) |
| CN (1) | CN1409639A (pt) |
| AT (1) | ATE403437T1 (pt) |
| AU (1) | AU768324B2 (pt) |
| CA (1) | CA2394862C (pt) |
| DE (1) | DE60039783D1 (pt) |
| DK (1) | DK1237575T3 (pt) |
| ES (1) | ES2311483T3 (pt) |
| IL (1) | IL149890A0 (pt) |
| NZ (1) | NZ519222A (pt) |
| PT (1) | PT1237575E (pt) |
| WO (1) | WO2001043773A1 (pt) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7160541B2 (en) | 2000-09-01 | 2007-01-09 | The Center For Blood Research, Inc. | Modified polypeptides stabilized in a desired conformation and methods for producing same |
| IL157706A0 (en) * | 2001-03-02 | 2004-03-28 | Medimmune Inc | METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING INTEGRIN alphav beta3 ANTAGONISTS |
| GB0111497D0 (en) * | 2001-05-11 | 2001-07-04 | Medical Res Council | Therapeutic methods |
| PL215168B1 (pl) | 2002-02-27 | 2013-10-31 | Immunex Corp | Formulacja polipeptydowa |
| EP3210624A1 (en) * | 2002-02-27 | 2017-08-30 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| WO2004026406A1 (en) * | 2002-09-20 | 2004-04-01 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
| WO2005039502A2 (en) * | 2003-10-24 | 2005-05-06 | Azopax Therapeutics Llc | Macromer-melt formulations |
| ATE551339T1 (de) | 2003-11-05 | 2012-04-15 | Sarcode Bioscience Inc | Modulatoren der zellulären adhäsion |
| US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
| US7871988B1 (en) * | 2005-01-04 | 2011-01-18 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| KR101465456B1 (ko) | 2005-05-16 | 2014-11-27 | 애브비 바이오테크놀로지 리미티드 | 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도 |
| CA2960117C (en) | 2005-05-17 | 2018-01-30 | Sarcode Bioscience Inc. | Lfa-1 antagonists for the treatment of eye disorders |
| EA012801B1 (ru) | 2005-06-14 | 2009-12-30 | Эмджен Инк. | Самобуферирующиеся композиции белков |
| EP1978997A1 (en) * | 2005-12-22 | 2008-10-15 | Apollo Life Sciences Limited | Transdermal delivery of pharmaceutical agents |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| WO2008063213A2 (en) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| EP2171451A4 (en) | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS |
| MX2010004281A (es) | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
| WO2009128934A1 (en) * | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
| US8080562B2 (en) * | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| CN102065694A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂 |
| WO2011063127A1 (en) | 2009-11-18 | 2011-05-26 | University Of Medicine And Dentistry Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| CA2770124C (en) * | 2009-08-06 | 2014-01-07 | Anitox Corporation | Water and feed preservative |
| WO2011050175A1 (en) | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| US9849192B2 (en) | 2009-11-18 | 2017-12-26 | Rutgers, The State University Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| US20120252893A1 (en) * | 2010-08-27 | 2012-10-04 | Julio Pimentel | Antimicrobial formulation |
| CA2848777A1 (en) | 2011-10-20 | 2013-04-25 | Anitox Corporation | Antimicrobial formulations with pelargonic acid |
| ES2859788T3 (es) | 2011-11-30 | 2021-10-04 | Anitox Corp | Mezcla antimicrobiana de aldehídos, ácidos orgánicos y ésteres de ácidos orgánicos |
| IN2015DN00847A (pt) | 2012-07-25 | 2015-06-12 | Sarcode Bioscience Inc | |
| WO2014046631A1 (en) | 2012-09-19 | 2014-03-27 | Tezcaner Aysen | CONTROLED DRUG DELIVERY SYSTEMS FOR ANTI-TNF-α |
| CA2887037A1 (en) | 2012-10-02 | 2014-04-10 | Rutgers, The State University Of New Jersey | Specific delivery of toxins conjugated with antibodies to activated matriptase |
| US20180079796A1 (en) * | 2015-03-13 | 2018-03-22 | Samsung Bioepis Co., Ltd. | Anti-tnf-alpha polypeptide composition and use thereof |
| RU2613056C1 (ru) * | 2016-03-14 | 2017-03-15 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) | Способ прогнозирования развития увеита у детей с ювенильным идиопатическим артритом |
| JP7145374B2 (ja) | 2016-03-18 | 2022-10-03 | ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー | インビボでの切断可能連結部分によって抗マトリプターゼ抗体にコンジュゲートされた化学療法剤を用いる腫瘍細胞の標的化 |
| MX2019004580A (es) | 2016-10-21 | 2019-08-12 | Amgen Inc | Formulaciones farmaceuticas y metodos para prepararlas. |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| IL83878A (en) * | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
| US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5690933A (en) * | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
| US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5945397A (en) * | 1989-09-05 | 1999-08-31 | Immunex Corporation | Purified p75 (type II) tumor necrosis factor receptor polypeptides |
| NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
| US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| GB9115364D0 (en) * | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2140933A1 (en) * | 1992-08-21 | 1994-02-22 | Paula M. Jardieu | Method for treating an lfa-1 mediated disorder |
| NZ257484A (en) * | 1992-11-03 | 1997-08-22 | Gene Shears Pty Ltd | Nucleotides active against tnf-alpha, treatment of viral diseases |
| ATE204299T1 (de) * | 1993-03-05 | 2001-09-15 | Bayer Ag | Humane monoklonale anti-tnf alpha antikörper |
| US5594106A (en) * | 1993-08-23 | 1997-01-14 | Immunex Corporation | Inhibitors of TNF-α secretion |
| JPH09510952A (ja) * | 1993-10-06 | 1997-11-04 | ザ ケネディー インスティチュート オブ リューマトロジー | 自己免疫疾患および炎症性疾患の治療 |
| JPH10130240A (ja) * | 1996-10-30 | 1998-05-19 | Dai Ichi Seiyaku Co Ltd | Ｉｃａｍ−１産生阻害剤 |
| DK0936923T3 (da) * | 1996-11-15 | 2004-04-26 | Kennedy Inst Of Rheumatology | Undertrykkelse af TNFalpha og IL-12 ved terapi |
| DK0941344T3 (da) * | 1996-11-27 | 2004-09-27 | Genentech Inc | Humaniserede anti-CD11a-antistoffer |
| US6037454A (en) * | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| WO1998024463A2 (en) * | 1996-12-06 | 1998-06-11 | Amgen Inc. | Combination therapy using a tnf binding protein for treating tnf-mediated diseases |
-
2000
- 2000-12-14 DK DK00986377T patent/DK1237575T3/da active
- 2000-12-14 PT PT00986377T patent/PT1237575E/pt unknown
- 2000-12-14 KR KR1020027007537A patent/KR100567292B1/ko not_active IP Right Cessation
- 2000-12-14 NZ NZ519222A patent/NZ519222A/en not_active IP Right Cessation
- 2000-12-14 CN CN00817171A patent/CN1409639A/zh active Pending
- 2000-12-14 DE DE60039783T patent/DE60039783D1/de not_active Expired - Lifetime
- 2000-12-14 CA CA2394862A patent/CA2394862C/en not_active Expired - Fee Related
- 2000-12-14 IL IL14989000A patent/IL149890A0/xx unknown
- 2000-12-14 AT AT00986377T patent/ATE403437T1/de not_active IP Right Cessation
- 2000-12-14 AU AU54397/01A patent/AU768324B2/en not_active Ceased
- 2000-12-14 EP EP00986377A patent/EP1237575B1/en not_active Expired - Lifetime
- 2000-12-14 WO PCT/US2000/033875 patent/WO2001043773A1/en active IP Right Grant
- 2000-12-14 ES ES00986377T patent/ES2311483T3/es not_active Expired - Lifetime
- 2000-12-14 JP JP2001544909A patent/JP2003517022A/ja active Pending
- 2000-12-14 US US09/738,540 patent/US20010031260A1/en not_active Abandoned
-
2005
- 2005-05-12 US US11/128,912 patent/US20050214291A1/en not_active Abandoned
-
2007
- 2007-07-26 US US11/828,977 patent/US20080031875A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1237575A1 (en) | 2002-09-11 |
| US20080031875A1 (en) | 2008-02-07 |
| ES2311483T3 (es) | 2009-02-16 |
| JP2003517022A (ja) | 2003-05-20 |
| CA2394862C (en) | 2011-10-11 |
| AU768324B2 (en) | 2003-12-11 |
| PT1237575E (pt) | 2008-11-17 |
| KR20020068372A (ko) | 2002-08-27 |
| AU5439701A (en) | 2001-06-25 |
| CN1409639A (zh) | 2003-04-09 |
| DK1237575T3 (da) | 2008-12-08 |
| NZ519222A (en) | 2004-04-30 |
| ATE403437T1 (de) | 2008-08-15 |
| US20010031260A1 (en) | 2001-10-18 |
| KR100567292B1 (ko) | 2006-04-04 |
| EP1237575B1 (en) | 2008-08-06 |
| CA2394862A1 (en) | 2001-06-21 |
| US20050214291A1 (en) | 2005-09-29 |
| WO2001043773A1 (en) | 2001-06-21 |
| DE60039783D1 (de) | 2008-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL149890A0 (en) | Tnt-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated | |
| UA85055C2 (ru) | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний | |
| AU7321598A (en) | Use of cholinesterase inhibitors to treat disorders of attention | |
| IL138476A0 (en) | Method for treating pharmaceutical compositions by special use of anti-oxidant | |
| MXPA05003501A (es) | Metodos para tratamiento del dolor administrando un antagonista del factor de crecimiento del nervio y un analgesico opioide y composiciones que los contienen. | |
| MX9602818A (es) | Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige. | |
| IL148071A0 (en) | Method for treatment of symptoms of central nervous system disorders | |
| ATE320803T1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
| UA66865C2 (uk) | Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти) | |
| AU2002241736A1 (en) | Method for preventing or treating pain by administering an endothelin antagonist | |
| EA200100930A1 (ru) | Способ лечения хозл | |
| CA2296560A1 (en) | Amino acid derivatives useful to treat stroke | |
| EP1056458A4 (en) | METHODS FOR TREATING PAIN, INCLUDING CHRONIC AND WOMAN-SPECIFIC PAIN | |
| YU89003A (sh) | Prevencija zavisnosti u terapiji bola | |
| EP1083914A4 (en) | TREATING ARTHRITIS AND OTHER SIMILAR DISORDERS | |
| MXPA02002315A (es) | Metodos y composiciones para reducir los niveles de fosfato en suero. | |
| AU4937499A (en) | Use of succinic acid or salts thereof and method of treating insulin resistance | |
| AU5434899A (en) | Cancer treatment | |
| EP1009421A4 (en) | PROCESS AND COMPOSITIONS FOR IMPROVED Wounds Healing | |
| EA199800822A1 (ru) | Способ лечения избыточной агрессии | |
| AU8680998A (en) | Method for preventing or treating erectile dysfunction by administering an endothelin antagonist | |
| AU2001262378A1 (en) | Method for treating cryptorchidism | |
| UA33498A (uk) | Спосіб лікування терапевтично резистентних форм шизофренії | |
| UA32108A (uk) | Спосіб лікування хронічного тонзиліту | |
| UA35854A (uk) | Спосіб лікування приховано протікаючого силікотуберкульозу |